Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis.
Animals
Capillary Permeability
/ drug effects
Cyclohexanecarboxylic Acids
/ pharmacology
Endothelial Cells
/ drug effects
Gene Knockout Techniques
Leukotriene Antagonists
/ pharmacology
Lung Neoplasms
/ drug therapy
Male
Mice
Mice, Inbred C57BL
Neoplasm Metastasis
/ drug therapy
Neoplasm Transplantation
Neoplasms, Experimental
Neovascularization, Pathologic
/ chemically induced
Phthalic Acids
/ pharmacology
Receptors, Leukotriene
/ drug effects
angiogenesis
cysteinyl leukotriene receptors
endothelial cells
metastasis
tumor growth
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
02 01 2019
02 01 2019
Historique:
pubmed:
19
12
2018
medline:
19
3
2019
entrez:
19
12
2018
Statut:
ppublish
Résumé
Cysteinyl leukotrienes (cys-LTs) are proinflammatory mediators that enhance vascular permeability through distinct receptors (CysLTRs). We found that CysLT
Identifiants
pubmed: 30559191
pii: 1817325115
doi: 10.1073/pnas.1817325115
pmc: PMC6320507
doi:
Substances chimiques
3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)propoxy)benzoic acid
0
Cyclohexanecarboxylic Acids
0
Leukotriene Antagonists
0
Phthalic Acids
0
Receptors, Leukotriene
0
cysteinyl leukotriene receptor 2
AJT72OTM42
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-204Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL119705
Pays : United States
Organisme : NCI NIH HHS
ID : R15 CA202847
Pays : United States
Organisme : NHLBI NIH HHS
ID : R15 HL106442
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Biochem Biophys Res Commun. 1989 Mar 15;159(2):572-8
pubmed: 2467671
Nat Rev Drug Discov. 2011 Jun;10(6):417-27
pubmed: 21629292
J Immunol. 2012 Nov 1;189(9):4556-65
pubmed: 23002438
Nature. 2007 Aug 2;448(7153):609-12
pubmed: 17632548
FASEB J. 2012 Mar;26(3):1100-9
pubmed: 22131271
J Pharmacol Exp Ther. 2011 Dec;339(3):768-78
pubmed: 21903747
Nature. 2015 Dec 17;528(7582):413-7
pubmed: 26649828
J Clin Invest. 2003 Oct;112(8):1142-51
pubmed: 14561699
J Biol Chem. 2004 Oct 29;279(44):46129-34
pubmed: 15328359
J Biol Chem. 2002 Jun 7;277(23):20820-4
pubmed: 11932261
Nat Genet. 2016 Jun;48(6):675-80
pubmed: 27089179
J Biol Chem. 2016 Apr 1;291(14):7242-55
pubmed: 26846851
Oncogene. 2016 Jan 21;35(3):314-22
pubmed: 25867067
Blood. 2007 Jun 1;109(11):4761-8
pubmed: 17327403
Eur J Cancer. 2010 Mar;46(4):826-35
pubmed: 20064706
Cardiovasc Res. 2011 Dec 1;92(3):456-65
pubmed: 21908648
Sci Rep. 2015 Sep 21;5:14257
pubmed: 26388427
PLoS One. 2013 Aug 15;8(8):e71536
pubmed: 23977066
Cardiovasc Res. 2010 May 1;86(2):226-35
pubmed: 20154066
Carcinogenesis. 2016 May;37(5):491-9
pubmed: 26979937
Pulm Pharmacol Ther. 2001;14(1):3-19
pubmed: 11162414
Cell. 1992 Aug 7;70(3):389-99
pubmed: 1643657
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16695-700
pubmed: 18931305
Eur J Pharmacol. 1994 Jun 2;258(1-2):151-4
pubmed: 7523148
J Vis Exp. 2009 Nov 24;(33):
pubmed: 19935640
Sci Rep. 2013 Nov 20;3:3274
pubmed: 24253666
Pharmazie. 2010 Oct;65(10):750-4
pubmed: 21105577
Sci Immunol. 2018 Oct 5;3(28):
pubmed: 30291131
Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):4992-7
pubmed: 22416124
Trends Cardiovasc Med. 2008 Oct;18(7):268-73
pubmed: 19232956
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6326-31
pubmed: 16606835
Proc Natl Acad Sci U S A. 2016 May 31;113(22):6242-7
pubmed: 27185938
Cancer Res. 2000 Dec 15;60(24):7163-9
pubmed: 11156426
J Invest Dermatol. 1983 Feb;80(2):115-9
pubmed: 6296237
Mediators Inflamm. 2017;2017:2432958
pubmed: 28932020
Biochem Pharmacol. 2009 Sep 15;78(6):539-52
pubmed: 19413999
Annu Rev Physiol. 2010;72:463-93
pubmed: 20148685
J Biol Chem. 2008 Jun 13;283(24):16477-87
pubmed: 18411276